Page 5 - 2019_05-HaematologicaMondo-web

haematologica Journal of the Ferrata Storti Foundation
Table of Contents
Volume 104, Issue 5: May 2019
Cover Figure
Peripheral blood smear from a patient with primary myelofibrosis showing thrombocytosis with platelet anisocytosis and marked mor- phological alterations. Courtesy of Prof. Rosangela Invernizzi.
Editorials
857 Factor H: a novel modulator in sickle cell disease Wassim El Nemer and Bérengère Koehl
859 A post-transplant optimized transplant-specific risk score in myelodysplastic syndromes Mahasweta Gooptu and John Koreth
862 Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia? Giuseppe Saglio et al.
864 Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all for one or none for all? William Johnson et al.
Perspective Article
868 Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia Ross L. Levine and Peter J.M. Valk
Review Articles
872 Evolutionary trajectory of leukemic clones and its clinical implications Amos Tuval and Liran I Shlush
881 CRISPR to fix bad blood: a new tool in basic and clinical hematology Elisa González-Romero et al.
Articles
Hematopoiesis
894 Long noncoding RNAs of single hematopoietic stem and progenitor cells in healthy and dysplastic human bone marrow Zhijie Wu et al.
Red Cell Biology & its Disorders
907 Finely-tuned regulation of AMP-activated protein kinase is crucial for human adult erythropoiesis Meriem Ladli et al.
919 Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule Elisabetta Lombardi et al.
Myelodysplastic Syndromes
929 Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation Nico Gagelmann et al.
Myeloproliferative Neoplasms
937 Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms
Alicia Arenas Cortés et al.
947 EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis Alessandro M. Vannucchi et al.
Chronic Myeloid Leukemia
955 Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
Christian Michel et al.
Acute Myeloid Leukemia
Haematologica 2019; vol. 104 no. 5 - May 2019 http://www.haematologica.org/